Overview

Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin

Status:
Completed

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

Summary

To assess the efficacy of D961H 20 mg once daily (q.d.) versus placebo in continuous treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily Low-dose aspirin therapy by evaluating time from randomisation to occurrence of gastric and/or duodenal ulcers.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Aspirin
Esomeprazole